View ValuationCell Impact 将来の成長Future 基準チェック /06現在、 Cell Impactの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Machinery 収益成長12.9%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報お知らせ • Aug 23Cell Impact AB (Publ) Provides Earnings Guidance for the Year 2027 and 2030Cell Impact AB (publ) provided earnings guidance for the year 2027 and 2030. For the year 2027, the company targets sales of SEK 200 million- SEK 250 million. For the year 2030, the company targets sales of more than SEK 600 million.お知らせ • Oct 24Cell Impact AB (Publ) Announces Preliminary Earnings Guidance for Third Quarter 2023Cell Impact AB (publ) announced preliminary EBIT for Third Quarter 2023. For the quarter, the company expects Net sales during Third Quarter 2023 preliminarily amounted to approximately SEK 9 million (17), which is slightly higher than the approximately SEK 8 million that the Company has indicated earlier, but still lower than previous expectations. The cost savings have already started to have some effect during Third Quarter 2023 - despite the significantly reduced sales, EBIT for the quarter is preliminarily around SEK -24 million, which is a smaller loss compared to both the corresponding quarter of the previous year and the first two quarters of 2023.お知らせ • Aug 24Cell Impact AB (publ) Provides Earnings Guidance for the Year 2025 and 2028Cell Impact AB (publ) provided earnings guidance for the year 2025 and 2028. For the year, the company targets sales of SEK 200 million- SEK 250 million.For the year, the company targets sales of more than SEK 600 million.すべての更新を表示Recent updatesReported Earnings • Aug 05Second quarter 2026 earnings released: kr0.036 loss per share (vs kr0.30 loss in 2Q 2025)Second quarter 2026 results: kr0.036 loss per share (improved from kr0.30 loss in 2Q 2025). Net loss: kr17.6m (loss narrowed 17% from 2Q 2025).お知らせ • Jul 02Malin Lundberg to Leave Cell Impact AB as CFO and Remain with the Company Until 30 September 2026Cell Impact AB announced that Malin Lundberg had decided to leave her position as CFO and would remain with the company until September 30, 2026. Malin Lundberg was appointed CFO in February 2024, having previously served as Business Controller since 2021. Responsibility for the company's accounting and financial reporting activities would be assumed internally. The company did not intend to appoint a successor immediately and would revisit the recruitment process once anticipated key orders had been secured.Reported Earnings • May 18First quarter 2026 earnings released: kr0.053 loss per share (vs kr0.31 loss in 1Q 2025)First quarter 2026 results: kr0.053 loss per share (improved from kr0.31 loss in 1Q 2025). Net loss: kr18.5m (loss narrowed 14% from 1Q 2025).Reported Earnings • Mar 25Full year 2025 earnings released: kr0.78 loss per share (vs kr0.16 loss in FY 2024)Full year 2025 results: kr0.78 loss per share (further deteriorated from kr0.16 loss in FY 2024). Net loss: kr132.0m (loss widened 31% from FY 2024).お知らせ • Mar 21Cell Impact AB (publ), Annual General Meeting, Apr 23, 2026Cell Impact AB (publ), Annual General Meeting, Apr 23, 2026, at 14:00 W. Europe Standard Time. Location: at the premises of sturegatan 15, by hantverket on sturegatan 15, stockholm SwedenReported Earnings • Feb 05Full year 2025 earnings released: kr0.78 loss per share (vs kr1.63 loss in FY 2024)Full year 2025 results: kr0.78 loss per share. Net loss: kr132.0m (loss widened 31% from FY 2024).お知らせ • Feb 04+ 4 more updatesCell Impact AB (publ) to Report Q1, 2026 Results on May 13, 2026Cell Impact AB (publ) announced that they will report Q1, 2026 results at 9:00 AM, Central European Standard Time on May 13, 2026Reported Earnings • Nov 09Third quarter 2025 earnings released: kr0.14 loss per share (vs kr0.30 loss in 3Q 2024)Third quarter 2025 results: kr0.14 loss per share. Net loss: kr22.8m (loss widened 28% from 3Q 2024).Recent Insider Transactions • Sep 03Independent Director recently bought kr170k worth of stockOn the 27th of August, Lars Bergström bought around 1m shares on-market at roughly kr0.17 per share. This transaction amounted to 95% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.Reported Earnings • Aug 24Second quarter 2025 earnings released: kr0.03 loss per share (vs kr0.035 loss in 2Q 2024)Second quarter 2025 results: kr0.03 loss per share. Net loss: kr21.2m (loss widened 1.7% from 2Q 2024).New Risk • Jul 29New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 66% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (25% average weekly change). Earnings have declined by 17% per year over the past 5 years. Shareholders have been substantially diluted in the past year (66% increase in shares outstanding). Market cap is less than US$10m (kr19.5m market cap, or US$2.02m). Minor Risk Revenue is less than US$5m (kr34m revenue, or US$3.5m).New Risk • Jul 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 349% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Earnings have declined by 17% per year over the past 5 years. Shareholders have been substantially diluted in the past year (349% increase in shares outstanding). Market cap is less than US$10m (kr67.8m market cap, or US$6.95m). Minor Risk Revenue is less than US$5m (kr34m revenue, or US$3.5m).お知らせ • May 20Cell Impact AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 62.664402 million.Cell Impact AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 62.664402 million. Security Name: Series B Shares Security Type: Common Stock Securities Offered: 3,133,220,076 Price\Range: SEK 0.02 Transaction Features: Rights OfferingReported Earnings • May 15First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: kr1.99m (down 67% from 1Q 2024). Net loss: kr21.5m (loss narrowed 8.1% from 1Q 2024).お知らせ • Apr 24Cell Impact AB (Publ) Announces Board ChangesCell Impact AB (publ) at the annual general meeting held on 24 April 2025 Mats Boquist was elected chairman of the board. The annual general meeting elected Mattias Klintemar, the chairman of the board and Kjell Östergren as members of the nomination committee for the period until the end of the next annual general meeting. Mattias Klintemar was re-elected as chairman of the nomination committee.Reported Earnings • Mar 23Full year 2024 earnings released: kr0.16 loss per share (vs kr1.11 loss in FY 2023)Full year 2024 results: kr0.16 loss per share (improved from kr1.11 loss in FY 2023). Revenue: kr37.9m (down 20% from FY 2023). Net loss: kr100.4m (loss narrowed 17% from FY 2023).お知らせ • Mar 21Cell Impact AB (publ), Annual General Meeting, Apr 24, 2025Cell Impact AB (publ), Annual General Meeting, Apr 24, 2025, at 14:00 W. Europe Standard Time. Location: at the premises of sturegatan 15 konferens, & event on sturegatan 15, stockholm SwedenNew Risk • Mar 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr77m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 19% per year over the past 5 years. Market cap is less than US$10m (kr89.1m market cap, or US$8.83m). Minor Risks Shareholders have been diluted in the past year (18% increase in shares outstanding). Revenue is less than US$5m (kr38m revenue, or US$3.8m).Reported Earnings • Feb 15Full year 2024 earnings released: kr0.16 loss per share (vs kr1.11 loss in FY 2023)Full year 2024 results: kr0.16 loss per share (improved from kr1.11 loss in FY 2023). Revenue: kr37.9m (down 20% from FY 2023). Net loss: kr100.4m (loss narrowed 17% from FY 2023).お知らせ • Feb 14+ 4 more updatesCell Impact AB (publ) to Report Q2, 2025 Results on Aug 22, 2025Cell Impact AB (publ) announced that they will report Q2, 2025 results on Aug 22, 2025New Risk • Feb 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr106m free cash flow). Earnings have declined by 21% per year over the past 5 years. Market cap is less than US$10m (kr86.3m market cap, or US$7.94m). Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Shareholders have been diluted in the past year (18% increase in shares outstanding). Revenue is less than US$5m (kr37m revenue, or US$3.4m).New Risk • Dec 16New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr108.9m (US$10.00m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr106m free cash flow). Earnings have declined by 21% per year over the past 5 years. Market cap is less than US$10m (kr108.9m market cap, or US$10.00m). Minor Risks Share price has been volatile over the past 3 months (8.8% average weekly change). Shareholders have been diluted in the past year (18% increase in shares outstanding). Revenue is less than US$5m (kr37m revenue, or US$3.4m).お知らせ • Nov 06+ 1 more updateCell Impact AB (publ) to Report Fiscal Year 2024 Final Results on Mar 20, 2025Cell Impact AB (publ) announced that they will report fiscal year 2024 final results at 12:00 PM, Central European Standard Time on Mar 20, 2025Recent Insider Transactions Derivative • Sep 23Chairman of the Board exercised options to buy kr76k worth of stock.On the 17th of September, Mats Franzén exercised options to buy 392k shares at a strike price of around kr0.17, costing a total of kr67k. This transaction amounted to 25% of their direct individual holding at the time of the trade. Since December 2023, Mats' direct individual holding has increased from 1.59m shares to 1.99m. Company insiders have collectively bought kr396k more than they sold, via options and on-market transactions, in the last 12 months.お知らせ • Sep 10Cell Impact AB (Publ) Announces Daniel Vallin as the Permanent CEO, Effective from October 1, 2024The Board of Directors has appointed Daniel Vallin as the permanent CEO of Cell Impact. Daniel Vallin has been serving as interim CEO since January 1, 2024. Daniel Vallin, with extensive industrial experience from companies such as Scania CV AB, was recruited to Cell Impact as COO in 2021 and has been the interim CEO of Cell Impact since the beginning of 2024. Today, the board of directors of Cell Impact has appointed him as the permanent CEO with effect from October 1, 2024.Recent Insider Transactions • Sep 05Director recently bought kr125k worth of stockOn the 3rd of September, Lars Bergstrom bought around 500k shares on-market at roughly kr0.25 per share. This transaction amounted to 91% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr330k more in shares than they have sold in the last 12 months.Reported Earnings • Aug 25Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: kr24.0m (up 37% from 2Q 2023). Net loss: kr20.9m (loss narrowed 27% from 2Q 2023).お知らせ • Aug 23Cell Impact AB (Publ) Provides Earnings Guidance for the Year 2027 and 2030Cell Impact AB (publ) provided earnings guidance for the year 2027 and 2030. For the year 2027, the company targets sales of SEK 200 million- SEK 250 million. For the year 2030, the company targets sales of more than SEK 600 million.お知らせ • Jul 03Cell Impact Adds Sealing as A New Part of Production ProcessCell Impact AB (publ) continues to develop its production process to better meet customer demand. The latest addition to the company’s production process is the opportunity to seal bipolar flow plates through dispersion. Sealing is a critical part of the assembly of bipolar flow plates for fuel cells and electrolyzers. Dispensing is one of the most popular sealing solutions used in the industry today.New Risk • May 29New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr159m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 24% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 6x increase in shares outstanding). Minor Risks Revenue is less than US$5m (kr34m revenue, or US$3.2m). Market cap is less than US$100m (kr189.3m market cap, or US$17.9m).Reported Earnings • May 15First quarter 2024 earnings released: kr0.04 loss per share (vs kr0.40 loss in 1Q 2023)First quarter 2024 results: kr0.04 loss per share (improved from kr0.40 loss in 1Q 2023). Revenue: kr6.10m (down 70% from 1Q 2023). Net loss: kr23.4m (loss narrowed 23% from 1Q 2023).お知らせ • Apr 26Cell Impact AB (Publ) Announces Board and Committee ChangesCell Impact AB (publ) announced that at the AGM held on 25 April 2024, elected Jan Pieters and Mats Boquist as board members for the period until the end of the next annual general meeting. Mats Franzén was elected chairman of the board. The annual general meeting elected Mattias Klintemar, the chairman of the board and Kjell Östergren as members of the nomination committee for the period until the end of the next annual general meeting. Mattias Klintemar was re-elected as chairman of the nomination committee.Recent Insider Transactions • Mar 14Director recently bought kr91k worth of stockOn the 8th of March, Lars Bergstrom bought around 500k shares on-market at roughly kr0.18 per share. This transaction increased Lars' direct individual holding by 10x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr444k more in shares than they have sold in the last 12 months.Reported Earnings • Feb 18Full year 2023 earnings released: kr1.11 loss per share (vs kr1.38 loss in FY 2022)Full year 2023 results: kr1.11 loss per share. Revenue: kr47.7m (down 48% from FY 2022). Net loss: kr121.4m (loss widened 17% from FY 2022).お知らせ • Jan 18+ 1 more updateCell Impact AB (Publ) Appoints Henrik Jackman as Chief Application EngineerCell Impact AB (publ) announced appointment of Henrik Jackman as Chief Application Engineer. The company's management already includes Daniel Vallin, CEO, Karina Sick Larsson, CHRO and Stefan Axellie, CFO (Malin Lundberg from February 12).Recent Insider Transactions • Dec 22Chief Executive Officer recently bought kr50k worth of stockOn the 20th of December, Pär Teike bought around 238k shares on-market at roughly kr0.21 per share. This transaction increased Pär's direct individual holding by 1x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Pär has been a buyer over the last 12 months, purchasing a net total of kr202k worth in shares.お知らせ • Dec 20Cell Impact AB (publ) Announces CEO ChangesCell Impact AB (publ) announced that Pär Teike, CEO since 2017, has decided to leave his role and Cell Impact. Daniel Vallin, Cell Impact's COO since 2021, is proposed to take over as acting CEO from January 1, 2024, until a decision is made regarding a permanent CEO of Cell Impact. Daniel Vallin, 46 years old, is a Master of Science in Industrial Engineering with extensive industrial experience from among others, Scania CV AB.New Risk • Dec 19New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 6x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr164m free cash flow). Share price has been highly volatile over the past 3 months (34% average weekly change). Earnings have declined by 24% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 6x increase in shares outstanding). Minor Risk Market cap is less than US$100m (kr159.7m market cap, or US$15.7m).お知らせ • Dec 13Cell Impact AB (Publ) Announces That Stefan Axellie to Leave Role as CFOCell Impact AB (publ) announced that Stefan Axellie, has decided to leave his role and Cell Impact by spring 2024. The process of identifying a successor will start within short. Stefan Axellie will stay on in his role until spring 2024 during the recruitment of his successor.Reported Earnings • Nov 05Third quarter 2023 earnings released: kr0.33 loss per share (vs kr0.38 loss in 3Q 2022)Third quarter 2023 results: kr0.33 loss per share (improved from kr0.38 loss in 3Q 2022). Revenue: kr9.19m (down 38% from 3Q 2022). Net loss: kr24.9m (loss narrowed 14% from 3Q 2022).お知らせ • Oct 24Cell Impact AB (Publ) Announces Preliminary Earnings Guidance for Third Quarter 2023Cell Impact AB (publ) announced preliminary EBIT for Third Quarter 2023. For the quarter, the company expects Net sales during Third Quarter 2023 preliminarily amounted to approximately SEK 9 million (17), which is slightly higher than the approximately SEK 8 million that the Company has indicated earlier, but still lower than previous expectations. The cost savings have already started to have some effect during Third Quarter 2023 - despite the significantly reduced sales, EBIT for the quarter is preliminarily around SEK -24 million, which is a smaller loss compared to both the corresponding quarter of the previous year and the first two quarters of 2023.New Risk • Oct 18New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr98.7m (US$8.95m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr163m free cash flow). Earnings have declined by 24% per year over the past 5 years. Market cap is less than US$10m (kr98.7m market cap, or US$8.95m). Minor Risk Share price has been volatile over the past 3 months (12% average weekly change).お知らせ • Sep 29Cell Impact AB (publ) Announces Anna Frick Will Leave the BoardCell Impact AB (publ) is announcing that board member Anna Frick will leave the board at her own request.Recent Insider Transactions • Aug 27Chief Executive Officer recently bought kr101k worth of stockOn the 24th of August, Pär Teike bought around 30k shares on-market at roughly kr3.37 per share. This transaction amounted to 17% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Pär has been a buyer over the last 12 months, purchasing a net total of kr296k worth in shares.お知らせ • Aug 24Cell Impact AB (publ) Provides Earnings Guidance for the Year 2025 and 2028Cell Impact AB (publ) provided earnings guidance for the year 2025 and 2028. For the year, the company targets sales of SEK 200 million- SEK 250 million.For the year, the company targets sales of more than SEK 600 million.お知らせ • Jul 04Cell Impact AB (Publ) Announces Outstanding Measuring Precision Enabling Customers' Product DevelopmentCell Impact AB (publ) announced that it is created by forming very thin sheets of metal with high velocity, in a single stroke, to create complex patterns. Extreme precision is required for the finished flow plate to work. With this new measuring technology, there is unique capacity to measure up to one-twentieth of a single strand of hair. To secure the best possible conditions, the measuring facility is built as a separate entity within the factory in Karlskoga. The slightest vibrations affect the measurement result - as do changes in temperature. Therefore, there is no contact between the room and external walls and the temperature is kept at 20 degrees around the clock, with a permissible variation of 0.4 degrees. The measuring equipment is used to measure flow plates, forming tools and fixtures. The investment in new measurement technology is part of Phase II, Cell Impact's strategy to develop its offering and productivity, which aims to better satisfy the customers' development objectives. The instruments include Hexagon Global Blue 7.10.7, Hexagon Global Blue 12.22.10 and Leitz PMM Gold 7.7.5, and gives Cell Impact better opportunities to measure complex geometries quickly, accurately, and continuously.New Risk • Jun 20New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr188m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 24% per year over the past 5 years. Minor Risk Market cap is less than US$100m (kr337.1m market cap, or US$31.1m).Recent Insider Transactions • Jun 19Chief Executive Officer recently bought kr50k worth of stockOn the 16th of June, Pär Teike bought around 13k shares on-market at roughly kr4.01 per share. This transaction amounted to 7.8% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Pär has been a buyer over the last 12 months, purchasing a net total of kr195k worth in shares.分析記事 • May 13Health Check: How Prudently Does Cell Impact (STO:CI) Use Debt?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Reported Earnings • Feb 19Full year 2022 earnings released: kr1.38 loss per share (vs kr1.35 loss in FY 2021)Full year 2022 results: kr1.38 loss per share (further deteriorated from kr1.35 loss in FY 2021). Revenue: kr92.1m (up 13% from FY 2021). Net loss: kr104.2m (loss widened 31% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 27% per year, which means it is performing significantly worse than earnings.お知らせ • Feb 18+ 5 more updatesCell Impact AB (publ) to Report Fiscal Year 2023 Results on Mar 24, 2024Cell Impact AB (publ) announced that they will report fiscal year 2023 results on Mar 24, 2024分析記事 • Jan 14Is Cell Impact (STO:CI) Using Debt In A Risky Way?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Board Change • Nov 16No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. No independent directors (5 non-independent directors). Director Thomas Carlstrom is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.Reported Earnings • Nov 05Third quarter 2022 earnings released: kr0.38 loss per share (vs kr0.25 loss in 3Q 2021)Third quarter 2022 results: kr0.38 loss per share (further deteriorated from kr0.25 loss in 3Q 2021). Revenue: kr14.7m (down 47% from 3Q 2021). Net loss: kr28.9m (loss widened 97% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 11% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Aug 25Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: kr26.5m (up 27% from 2Q 2021). Net loss: kr22.2m (loss narrowed 6.6% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has increased by 52% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • May 06First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: kr21.7m (up 74% from 1Q 2021). Net loss: kr24.1m (loss widened 64% from 1Q 2021).Board Change • Apr 27No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. No independent directors (5 non-independent directors). Director Thomas Carlstrom is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.Reported Earnings • Mar 28Full year 2021 earnings released: kr1.35 loss per share (vs kr0.88 loss in FY 2020)Full year 2021 results: kr1.35 loss per share (down from kr0.88 loss in FY 2020). Revenue: kr81.8m (up 179% from FY 2020). Net loss: kr79.9m (loss widened 80% from FY 2020). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has increased by 48% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Feb 19Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: kr1.36 loss per share (down from kr0.88 loss in FY 2020). Revenue: kr81.8m (up 179% from FY 2020). Net loss: kr79.9m (loss widened 81% from FY 2020). Revenue missed analyst estimates by 40%. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has increased by 57% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Feb 19+ 5 more updatesCell Impact AB (publ) to Report Q2, 2022 Results on Aug 25, 2022Cell Impact AB (publ) announced that they will report Q2, 2022 results on Aug 25, 2022Reported Earnings • Oct 23Third quarter 2021 earnings releasedThe company reported a solid third quarter result with improved revenues and control over costs, although losses increased. Third quarter 2021 results: Revenue: kr27.5m (up 224% from 3Q 2020). Net loss: kr14.7m (loss widened 141% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has increased by 92% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Aug 26Second quarter 2021 earnings releasedThe company reported a solid second quarter result with improved revenues and control over costs, although losses increased. Second quarter 2021 results: Revenue: kr17.8m (up 271% from 2Q 2020). Net loss: kr23.8m (loss widened 73% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has increased by 79% per year, which means it is tracking significantly ahead of earnings growth.分析記事 • May 09Here's Why We're Not Too Worried About Cell Impact's (STO:CI B) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Reported Earnings • May 08First quarter 2021 earnings releasedThe company reported a solid first quarter result with improved revenues and control over costs, although losses increased. First quarter 2021 results: Revenue: kr12.5m (up 76% from 1Q 2020). Net loss: kr14.7m (loss widened 28% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has increased by 68% per year, which means it is tracking significantly ahead of earnings growth.お知らせ • Mar 14Cell Impact AB (publ) Receives SEK 42 Million Order from Plug Power for New Production Line and Flow PlatesCell Impact AB (publ) has received an order worth SEK 42 million from Plug Power Inc. for a Cell Impact FormingTM production line and flow plates for delivery during 2021. The production line will be installed at Plug Power's Innovation Center in Rochester, New York. Both Plug Power's Innovation Center and Cell Impact's Karlskoga production facility will produce and supply Plug Power with flow plates for their fuel cells. This dual sourcing structure aims to reduce the supply chain risk by implementing multisite production capability for flow plates.分析記事 • Feb 21Investors Who Bought Cell Impact (STO:CI B) Shares Three Years Ago Are Now Up 428%We think that it's fair to say that the possibility of finding fantastic multi-year winners is what motivates many...Reported Earnings • Feb 21Full year 2020 earnings released: kr0.85 loss per share (vs kr1.45 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: kr29.3m (up 146% from FY 2019). Net loss: kr44.3m (loss narrowed 8.5% from FY 2019). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has increased by 74% per year, which means it is tracking significantly ahead of earnings growth.Is New 90 Day High Low • Jan 22New 90-day high: kr49.70The company is up 106% from its price of kr24.15 on 23 October 2020. The Swedish market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Machinery industry, which is up 20% over the same period.お知らせ • Jan 13Cell Impact Appoints Forrest Zhang as Country Manager in China, Effective May 3, 2021Cell Impact AB (publ) announced that it has appointed Mr. Forrest Zhang as Country Manager in China. Mr. Zhang will be based in Shanghai and will begin his new position on May 3, 2021. Mr. Zhang is currently General Manager at ASSA ABLOY Crawford in Kunshan, China.分析記事 • Dec 27How Much Is Cell Impact AB (publ) (STO:CI B) Paying Its CEO?Pär Teike became the CEO of Cell Impact AB (publ) ( STO:CI B ) in 2017, and we think it's a good time to look at the...Is New 90 Day High Low • Dec 16New 90-day high: kr29.30The company is up 14% from its price of kr25.75 on 17 September 2020. The Swedish market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Machinery industry, which is up 10.0% over the same period.Is New 90 Day High Low • Nov 30New 90-day high: kr29.00The company is up 36% from its price of kr21.40 on 01 September 2020. The Swedish market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Machinery industry, which is up 14% over the same period.Reported Earnings • Nov 07Third quarter 2020 earnings released: kr0.12 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: kr8.50m (up 143% from 3Q 2019). Net loss: kr6.10m (loss narrowed 32% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth.Is New 90 Day High Low • Oct 29New 90-day low: kr21.35The company is down 28% from its price of kr29.65 on 30 July 2020. The Swedish market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 3.0% over the same period.お知らせ • Oct 08Cell Impact AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 175 million.Cell Impact AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 175 million. Security Name: Series B Shares Security Type: Common Stock Securities Offered: 7,000,000 Price\Range: SEK 25 Transaction Features: Subsequent Direct Listing このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Cell Impact は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OM:CI - アナリストの将来予測と過去の財務データ ( )SEK Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/20265-125-36-35N/A3/31/20266-129-46-44N/A12/31/20256-132-47-45N/A9/30/20257-104-53-49N/A6/30/202512-99-34-29N/A3/31/202534-99-45-36N/A12/31/202438-100-77-62N/A9/30/202437-100-106-81N/A6/30/202440-107-146-108N/A3/31/202434-114-159-113N/A12/31/202348-121-159-106N/A9/30/202365-113-164-114N/A6/30/202372-117-163-109N/A3/31/202376-111-188-125N/A12/31/202278-104-174-106N/A9/30/202281-102-178-103N/A6/30/202291-88-173-102N/A3/31/202291-89-149-88N/A12/31/202182-80-140-86N/A9/30/202170-66-126-77N/A6/30/202151-57-101-60N/A3/31/202135-47-77-43N/A12/31/202029-44-70-48N/A9/30/202022-49-50-36N/A6/30/202017-52-58-47N/A3/31/202017-50N/A-44N/A12/31/201912-48N/A-41N/A9/30/201912-44N/A-43N/A6/30/201911-47N/A-40N/A3/31/20198-48N/A-45N/A12/31/20187-45N/A-43N/A9/30/20184-40N/A-35N/A6/30/20181-33N/A-28N/A3/31/20181-23N/A-21N/A12/31/20172-18N/A-16N/A9/30/20173-14N/A-13N/A6/30/20173-11N/A-10N/A3/31/20173-8N/A-9N/A12/31/20162-9N/A-9N/A9/30/20162-7N/A-7N/A6/30/20162-7N/A-7N/A3/31/20161-8N/A-6N/A12/31/20152-7N/A-6N/A9/30/20152-8N/A-6N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: CIの予測収益成長が 貯蓄率 ( 2.1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: CIの収益がSwedish市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: CIの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: CIの収益がSwedish市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: CIの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: CIの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YCapital-goods 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/16 17:54終値2026/08/14 00:00収益2026/06/30年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Cell Impact AB (publ) 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Mats HyttingeCarlsquare AB
お知らせ • Aug 23Cell Impact AB (Publ) Provides Earnings Guidance for the Year 2027 and 2030Cell Impact AB (publ) provided earnings guidance for the year 2027 and 2030. For the year 2027, the company targets sales of SEK 200 million- SEK 250 million. For the year 2030, the company targets sales of more than SEK 600 million.
お知らせ • Oct 24Cell Impact AB (Publ) Announces Preliminary Earnings Guidance for Third Quarter 2023Cell Impact AB (publ) announced preliminary EBIT for Third Quarter 2023. For the quarter, the company expects Net sales during Third Quarter 2023 preliminarily amounted to approximately SEK 9 million (17), which is slightly higher than the approximately SEK 8 million that the Company has indicated earlier, but still lower than previous expectations. The cost savings have already started to have some effect during Third Quarter 2023 - despite the significantly reduced sales, EBIT for the quarter is preliminarily around SEK -24 million, which is a smaller loss compared to both the corresponding quarter of the previous year and the first two quarters of 2023.
お知らせ • Aug 24Cell Impact AB (publ) Provides Earnings Guidance for the Year 2025 and 2028Cell Impact AB (publ) provided earnings guidance for the year 2025 and 2028. For the year, the company targets sales of SEK 200 million- SEK 250 million.For the year, the company targets sales of more than SEK 600 million.
Reported Earnings • Aug 05Second quarter 2026 earnings released: kr0.036 loss per share (vs kr0.30 loss in 2Q 2025)Second quarter 2026 results: kr0.036 loss per share (improved from kr0.30 loss in 2Q 2025). Net loss: kr17.6m (loss narrowed 17% from 2Q 2025).
お知らせ • Jul 02Malin Lundberg to Leave Cell Impact AB as CFO and Remain with the Company Until 30 September 2026Cell Impact AB announced that Malin Lundberg had decided to leave her position as CFO and would remain with the company until September 30, 2026. Malin Lundberg was appointed CFO in February 2024, having previously served as Business Controller since 2021. Responsibility for the company's accounting and financial reporting activities would be assumed internally. The company did not intend to appoint a successor immediately and would revisit the recruitment process once anticipated key orders had been secured.
Reported Earnings • May 18First quarter 2026 earnings released: kr0.053 loss per share (vs kr0.31 loss in 1Q 2025)First quarter 2026 results: kr0.053 loss per share (improved from kr0.31 loss in 1Q 2025). Net loss: kr18.5m (loss narrowed 14% from 1Q 2025).
Reported Earnings • Mar 25Full year 2025 earnings released: kr0.78 loss per share (vs kr0.16 loss in FY 2024)Full year 2025 results: kr0.78 loss per share (further deteriorated from kr0.16 loss in FY 2024). Net loss: kr132.0m (loss widened 31% from FY 2024).
お知らせ • Mar 21Cell Impact AB (publ), Annual General Meeting, Apr 23, 2026Cell Impact AB (publ), Annual General Meeting, Apr 23, 2026, at 14:00 W. Europe Standard Time. Location: at the premises of sturegatan 15, by hantverket on sturegatan 15, stockholm Sweden
Reported Earnings • Feb 05Full year 2025 earnings released: kr0.78 loss per share (vs kr1.63 loss in FY 2024)Full year 2025 results: kr0.78 loss per share. Net loss: kr132.0m (loss widened 31% from FY 2024).
お知らせ • Feb 04+ 4 more updatesCell Impact AB (publ) to Report Q1, 2026 Results on May 13, 2026Cell Impact AB (publ) announced that they will report Q1, 2026 results at 9:00 AM, Central European Standard Time on May 13, 2026
Reported Earnings • Nov 09Third quarter 2025 earnings released: kr0.14 loss per share (vs kr0.30 loss in 3Q 2024)Third quarter 2025 results: kr0.14 loss per share. Net loss: kr22.8m (loss widened 28% from 3Q 2024).
Recent Insider Transactions • Sep 03Independent Director recently bought kr170k worth of stockOn the 27th of August, Lars Bergström bought around 1m shares on-market at roughly kr0.17 per share. This transaction amounted to 95% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
Reported Earnings • Aug 24Second quarter 2025 earnings released: kr0.03 loss per share (vs kr0.035 loss in 2Q 2024)Second quarter 2025 results: kr0.03 loss per share. Net loss: kr21.2m (loss widened 1.7% from 2Q 2024).
New Risk • Jul 29New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 66% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (25% average weekly change). Earnings have declined by 17% per year over the past 5 years. Shareholders have been substantially diluted in the past year (66% increase in shares outstanding). Market cap is less than US$10m (kr19.5m market cap, or US$2.02m). Minor Risk Revenue is less than US$5m (kr34m revenue, or US$3.5m).
New Risk • Jul 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 349% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Earnings have declined by 17% per year over the past 5 years. Shareholders have been substantially diluted in the past year (349% increase in shares outstanding). Market cap is less than US$10m (kr67.8m market cap, or US$6.95m). Minor Risk Revenue is less than US$5m (kr34m revenue, or US$3.5m).
お知らせ • May 20Cell Impact AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 62.664402 million.Cell Impact AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 62.664402 million. Security Name: Series B Shares Security Type: Common Stock Securities Offered: 3,133,220,076 Price\Range: SEK 0.02 Transaction Features: Rights Offering
Reported Earnings • May 15First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: kr1.99m (down 67% from 1Q 2024). Net loss: kr21.5m (loss narrowed 8.1% from 1Q 2024).
お知らせ • Apr 24Cell Impact AB (Publ) Announces Board ChangesCell Impact AB (publ) at the annual general meeting held on 24 April 2025 Mats Boquist was elected chairman of the board. The annual general meeting elected Mattias Klintemar, the chairman of the board and Kjell Östergren as members of the nomination committee for the period until the end of the next annual general meeting. Mattias Klintemar was re-elected as chairman of the nomination committee.
Reported Earnings • Mar 23Full year 2024 earnings released: kr0.16 loss per share (vs kr1.11 loss in FY 2023)Full year 2024 results: kr0.16 loss per share (improved from kr1.11 loss in FY 2023). Revenue: kr37.9m (down 20% from FY 2023). Net loss: kr100.4m (loss narrowed 17% from FY 2023).
お知らせ • Mar 21Cell Impact AB (publ), Annual General Meeting, Apr 24, 2025Cell Impact AB (publ), Annual General Meeting, Apr 24, 2025, at 14:00 W. Europe Standard Time. Location: at the premises of sturegatan 15 konferens, & event on sturegatan 15, stockholm Sweden
New Risk • Mar 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr77m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 19% per year over the past 5 years. Market cap is less than US$10m (kr89.1m market cap, or US$8.83m). Minor Risks Shareholders have been diluted in the past year (18% increase in shares outstanding). Revenue is less than US$5m (kr38m revenue, or US$3.8m).
Reported Earnings • Feb 15Full year 2024 earnings released: kr0.16 loss per share (vs kr1.11 loss in FY 2023)Full year 2024 results: kr0.16 loss per share (improved from kr1.11 loss in FY 2023). Revenue: kr37.9m (down 20% from FY 2023). Net loss: kr100.4m (loss narrowed 17% from FY 2023).
お知らせ • Feb 14+ 4 more updatesCell Impact AB (publ) to Report Q2, 2025 Results on Aug 22, 2025Cell Impact AB (publ) announced that they will report Q2, 2025 results on Aug 22, 2025
New Risk • Feb 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr106m free cash flow). Earnings have declined by 21% per year over the past 5 years. Market cap is less than US$10m (kr86.3m market cap, or US$7.94m). Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Shareholders have been diluted in the past year (18% increase in shares outstanding). Revenue is less than US$5m (kr37m revenue, or US$3.4m).
New Risk • Dec 16New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr108.9m (US$10.00m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr106m free cash flow). Earnings have declined by 21% per year over the past 5 years. Market cap is less than US$10m (kr108.9m market cap, or US$10.00m). Minor Risks Share price has been volatile over the past 3 months (8.8% average weekly change). Shareholders have been diluted in the past year (18% increase in shares outstanding). Revenue is less than US$5m (kr37m revenue, or US$3.4m).
お知らせ • Nov 06+ 1 more updateCell Impact AB (publ) to Report Fiscal Year 2024 Final Results on Mar 20, 2025Cell Impact AB (publ) announced that they will report fiscal year 2024 final results at 12:00 PM, Central European Standard Time on Mar 20, 2025
Recent Insider Transactions Derivative • Sep 23Chairman of the Board exercised options to buy kr76k worth of stock.On the 17th of September, Mats Franzén exercised options to buy 392k shares at a strike price of around kr0.17, costing a total of kr67k. This transaction amounted to 25% of their direct individual holding at the time of the trade. Since December 2023, Mats' direct individual holding has increased from 1.59m shares to 1.99m. Company insiders have collectively bought kr396k more than they sold, via options and on-market transactions, in the last 12 months.
お知らせ • Sep 10Cell Impact AB (Publ) Announces Daniel Vallin as the Permanent CEO, Effective from October 1, 2024The Board of Directors has appointed Daniel Vallin as the permanent CEO of Cell Impact. Daniel Vallin has been serving as interim CEO since January 1, 2024. Daniel Vallin, with extensive industrial experience from companies such as Scania CV AB, was recruited to Cell Impact as COO in 2021 and has been the interim CEO of Cell Impact since the beginning of 2024. Today, the board of directors of Cell Impact has appointed him as the permanent CEO with effect from October 1, 2024.
Recent Insider Transactions • Sep 05Director recently bought kr125k worth of stockOn the 3rd of September, Lars Bergstrom bought around 500k shares on-market at roughly kr0.25 per share. This transaction amounted to 91% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr330k more in shares than they have sold in the last 12 months.
Reported Earnings • Aug 25Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: kr24.0m (up 37% from 2Q 2023). Net loss: kr20.9m (loss narrowed 27% from 2Q 2023).
お知らせ • Aug 23Cell Impact AB (Publ) Provides Earnings Guidance for the Year 2027 and 2030Cell Impact AB (publ) provided earnings guidance for the year 2027 and 2030. For the year 2027, the company targets sales of SEK 200 million- SEK 250 million. For the year 2030, the company targets sales of more than SEK 600 million.
お知らせ • Jul 03Cell Impact Adds Sealing as A New Part of Production ProcessCell Impact AB (publ) continues to develop its production process to better meet customer demand. The latest addition to the company’s production process is the opportunity to seal bipolar flow plates through dispersion. Sealing is a critical part of the assembly of bipolar flow plates for fuel cells and electrolyzers. Dispensing is one of the most popular sealing solutions used in the industry today.
New Risk • May 29New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr159m free cash flow). Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 24% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 6x increase in shares outstanding). Minor Risks Revenue is less than US$5m (kr34m revenue, or US$3.2m). Market cap is less than US$100m (kr189.3m market cap, or US$17.9m).
Reported Earnings • May 15First quarter 2024 earnings released: kr0.04 loss per share (vs kr0.40 loss in 1Q 2023)First quarter 2024 results: kr0.04 loss per share (improved from kr0.40 loss in 1Q 2023). Revenue: kr6.10m (down 70% from 1Q 2023). Net loss: kr23.4m (loss narrowed 23% from 1Q 2023).
お知らせ • Apr 26Cell Impact AB (Publ) Announces Board and Committee ChangesCell Impact AB (publ) announced that at the AGM held on 25 April 2024, elected Jan Pieters and Mats Boquist as board members for the period until the end of the next annual general meeting. Mats Franzén was elected chairman of the board. The annual general meeting elected Mattias Klintemar, the chairman of the board and Kjell Östergren as members of the nomination committee for the period until the end of the next annual general meeting. Mattias Klintemar was re-elected as chairman of the nomination committee.
Recent Insider Transactions • Mar 14Director recently bought kr91k worth of stockOn the 8th of March, Lars Bergstrom bought around 500k shares on-market at roughly kr0.18 per share. This transaction increased Lars' direct individual holding by 10x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr444k more in shares than they have sold in the last 12 months.
Reported Earnings • Feb 18Full year 2023 earnings released: kr1.11 loss per share (vs kr1.38 loss in FY 2022)Full year 2023 results: kr1.11 loss per share. Revenue: kr47.7m (down 48% from FY 2022). Net loss: kr121.4m (loss widened 17% from FY 2022).
お知らせ • Jan 18+ 1 more updateCell Impact AB (Publ) Appoints Henrik Jackman as Chief Application EngineerCell Impact AB (publ) announced appointment of Henrik Jackman as Chief Application Engineer. The company's management already includes Daniel Vallin, CEO, Karina Sick Larsson, CHRO and Stefan Axellie, CFO (Malin Lundberg from February 12).
Recent Insider Transactions • Dec 22Chief Executive Officer recently bought kr50k worth of stockOn the 20th of December, Pär Teike bought around 238k shares on-market at roughly kr0.21 per share. This transaction increased Pär's direct individual holding by 1x at the time of the trade. This was the largest purchase by an insider in the last 3 months. Pär has been a buyer over the last 12 months, purchasing a net total of kr202k worth in shares.
お知らせ • Dec 20Cell Impact AB (publ) Announces CEO ChangesCell Impact AB (publ) announced that Pär Teike, CEO since 2017, has decided to leave his role and Cell Impact. Daniel Vallin, Cell Impact's COO since 2021, is proposed to take over as acting CEO from January 1, 2024, until a decision is made regarding a permanent CEO of Cell Impact. Daniel Vallin, 46 years old, is a Master of Science in Industrial Engineering with extensive industrial experience from among others, Scania CV AB.
New Risk • Dec 19New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Over 6x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr164m free cash flow). Share price has been highly volatile over the past 3 months (34% average weekly change). Earnings have declined by 24% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 6x increase in shares outstanding). Minor Risk Market cap is less than US$100m (kr159.7m market cap, or US$15.7m).
お知らせ • Dec 13Cell Impact AB (Publ) Announces That Stefan Axellie to Leave Role as CFOCell Impact AB (publ) announced that Stefan Axellie, has decided to leave his role and Cell Impact by spring 2024. The process of identifying a successor will start within short. Stefan Axellie will stay on in his role until spring 2024 during the recruitment of his successor.
Reported Earnings • Nov 05Third quarter 2023 earnings released: kr0.33 loss per share (vs kr0.38 loss in 3Q 2022)Third quarter 2023 results: kr0.33 loss per share (improved from kr0.38 loss in 3Q 2022). Revenue: kr9.19m (down 38% from 3Q 2022). Net loss: kr24.9m (loss narrowed 14% from 3Q 2022).
お知らせ • Oct 24Cell Impact AB (Publ) Announces Preliminary Earnings Guidance for Third Quarter 2023Cell Impact AB (publ) announced preliminary EBIT for Third Quarter 2023. For the quarter, the company expects Net sales during Third Quarter 2023 preliminarily amounted to approximately SEK 9 million (17), which is slightly higher than the approximately SEK 8 million that the Company has indicated earlier, but still lower than previous expectations. The cost savings have already started to have some effect during Third Quarter 2023 - despite the significantly reduced sales, EBIT for the quarter is preliminarily around SEK -24 million, which is a smaller loss compared to both the corresponding quarter of the previous year and the first two quarters of 2023.
New Risk • Oct 18New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr98.7m (US$8.95m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr163m free cash flow). Earnings have declined by 24% per year over the past 5 years. Market cap is less than US$10m (kr98.7m market cap, or US$8.95m). Minor Risk Share price has been volatile over the past 3 months (12% average weekly change).
お知らせ • Sep 29Cell Impact AB (publ) Announces Anna Frick Will Leave the BoardCell Impact AB (publ) is announcing that board member Anna Frick will leave the board at her own request.
Recent Insider Transactions • Aug 27Chief Executive Officer recently bought kr101k worth of stockOn the 24th of August, Pär Teike bought around 30k shares on-market at roughly kr3.37 per share. This transaction amounted to 17% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Pär has been a buyer over the last 12 months, purchasing a net total of kr296k worth in shares.
お知らせ • Aug 24Cell Impact AB (publ) Provides Earnings Guidance for the Year 2025 and 2028Cell Impact AB (publ) provided earnings guidance for the year 2025 and 2028. For the year, the company targets sales of SEK 200 million- SEK 250 million.For the year, the company targets sales of more than SEK 600 million.
お知らせ • Jul 04Cell Impact AB (Publ) Announces Outstanding Measuring Precision Enabling Customers' Product DevelopmentCell Impact AB (publ) announced that it is created by forming very thin sheets of metal with high velocity, in a single stroke, to create complex patterns. Extreme precision is required for the finished flow plate to work. With this new measuring technology, there is unique capacity to measure up to one-twentieth of a single strand of hair. To secure the best possible conditions, the measuring facility is built as a separate entity within the factory in Karlskoga. The slightest vibrations affect the measurement result - as do changes in temperature. Therefore, there is no contact between the room and external walls and the temperature is kept at 20 degrees around the clock, with a permissible variation of 0.4 degrees. The measuring equipment is used to measure flow plates, forming tools and fixtures. The investment in new measurement technology is part of Phase II, Cell Impact's strategy to develop its offering and productivity, which aims to better satisfy the customers' development objectives. The instruments include Hexagon Global Blue 7.10.7, Hexagon Global Blue 12.22.10 and Leitz PMM Gold 7.7.5, and gives Cell Impact better opportunities to measure complex geometries quickly, accurately, and continuously.
New Risk • Jun 20New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr188m free cash flow). Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 24% per year over the past 5 years. Minor Risk Market cap is less than US$100m (kr337.1m market cap, or US$31.1m).
Recent Insider Transactions • Jun 19Chief Executive Officer recently bought kr50k worth of stockOn the 16th of June, Pär Teike bought around 13k shares on-market at roughly kr4.01 per share. This transaction amounted to 7.8% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Pär has been a buyer over the last 12 months, purchasing a net total of kr195k worth in shares.
分析記事 • May 13Health Check: How Prudently Does Cell Impact (STO:CI) Use Debt?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Reported Earnings • Feb 19Full year 2022 earnings released: kr1.38 loss per share (vs kr1.35 loss in FY 2021)Full year 2022 results: kr1.38 loss per share (further deteriorated from kr1.35 loss in FY 2021). Revenue: kr92.1m (up 13% from FY 2021). Net loss: kr104.2m (loss widened 31% from FY 2021). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 27% per year, which means it is performing significantly worse than earnings.
お知らせ • Feb 18+ 5 more updatesCell Impact AB (publ) to Report Fiscal Year 2023 Results on Mar 24, 2024Cell Impact AB (publ) announced that they will report fiscal year 2023 results on Mar 24, 2024
分析記事 • Jan 14Is Cell Impact (STO:CI) Using Debt In A Risky Way?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Board Change • Nov 16No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. No independent directors (5 non-independent directors). Director Thomas Carlstrom is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
Reported Earnings • Nov 05Third quarter 2022 earnings released: kr0.38 loss per share (vs kr0.25 loss in 3Q 2021)Third quarter 2022 results: kr0.38 loss per share (further deteriorated from kr0.25 loss in 3Q 2021). Revenue: kr14.7m (down 47% from 3Q 2021). Net loss: kr28.9m (loss widened 97% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has increased by 11% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Aug 25Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: kr26.5m (up 27% from 2Q 2021). Net loss: kr22.2m (loss narrowed 6.6% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has increased by 52% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • May 06First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: kr21.7m (up 74% from 1Q 2021). Net loss: kr24.1m (loss widened 64% from 1Q 2021).
Board Change • Apr 27No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. No independent directors (5 non-independent directors). Director Thomas Carlstrom is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
Reported Earnings • Mar 28Full year 2021 earnings released: kr1.35 loss per share (vs kr0.88 loss in FY 2020)Full year 2021 results: kr1.35 loss per share (down from kr0.88 loss in FY 2020). Revenue: kr81.8m (up 179% from FY 2020). Net loss: kr79.9m (loss widened 80% from FY 2020). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has increased by 48% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Feb 19Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: kr1.36 loss per share (down from kr0.88 loss in FY 2020). Revenue: kr81.8m (up 179% from FY 2020). Net loss: kr79.9m (loss widened 81% from FY 2020). Revenue missed analyst estimates by 40%. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has increased by 57% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Feb 19+ 5 more updatesCell Impact AB (publ) to Report Q2, 2022 Results on Aug 25, 2022Cell Impact AB (publ) announced that they will report Q2, 2022 results on Aug 25, 2022
Reported Earnings • Oct 23Third quarter 2021 earnings releasedThe company reported a solid third quarter result with improved revenues and control over costs, although losses increased. Third quarter 2021 results: Revenue: kr27.5m (up 224% from 3Q 2020). Net loss: kr14.7m (loss widened 141% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 46% per year but the company’s share price has increased by 92% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Aug 26Second quarter 2021 earnings releasedThe company reported a solid second quarter result with improved revenues and control over costs, although losses increased. Second quarter 2021 results: Revenue: kr17.8m (up 271% from 2Q 2020). Net loss: kr23.8m (loss widened 73% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has increased by 79% per year, which means it is tracking significantly ahead of earnings growth.
分析記事 • May 09Here's Why We're Not Too Worried About Cell Impact's (STO:CI B) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Reported Earnings • May 08First quarter 2021 earnings releasedThe company reported a solid first quarter result with improved revenues and control over costs, although losses increased. First quarter 2021 results: Revenue: kr12.5m (up 76% from 1Q 2020). Net loss: kr14.7m (loss widened 28% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has increased by 68% per year, which means it is tracking significantly ahead of earnings growth.
お知らせ • Mar 14Cell Impact AB (publ) Receives SEK 42 Million Order from Plug Power for New Production Line and Flow PlatesCell Impact AB (publ) has received an order worth SEK 42 million from Plug Power Inc. for a Cell Impact FormingTM production line and flow plates for delivery during 2021. The production line will be installed at Plug Power's Innovation Center in Rochester, New York. Both Plug Power's Innovation Center and Cell Impact's Karlskoga production facility will produce and supply Plug Power with flow plates for their fuel cells. This dual sourcing structure aims to reduce the supply chain risk by implementing multisite production capability for flow plates.
分析記事 • Feb 21Investors Who Bought Cell Impact (STO:CI B) Shares Three Years Ago Are Now Up 428%We think that it's fair to say that the possibility of finding fantastic multi-year winners is what motivates many...
Reported Earnings • Feb 21Full year 2020 earnings released: kr0.85 loss per share (vs kr1.45 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: kr29.3m (up 146% from FY 2019). Net loss: kr44.3m (loss narrowed 8.5% from FY 2019). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has increased by 74% per year, which means it is tracking significantly ahead of earnings growth.
Is New 90 Day High Low • Jan 22New 90-day high: kr49.70The company is up 106% from its price of kr24.15 on 23 October 2020. The Swedish market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Machinery industry, which is up 20% over the same period.
お知らせ • Jan 13Cell Impact Appoints Forrest Zhang as Country Manager in China, Effective May 3, 2021Cell Impact AB (publ) announced that it has appointed Mr. Forrest Zhang as Country Manager in China. Mr. Zhang will be based in Shanghai and will begin his new position on May 3, 2021. Mr. Zhang is currently General Manager at ASSA ABLOY Crawford in Kunshan, China.
分析記事 • Dec 27How Much Is Cell Impact AB (publ) (STO:CI B) Paying Its CEO?Pär Teike became the CEO of Cell Impact AB (publ) ( STO:CI B ) in 2017, and we think it's a good time to look at the...
Is New 90 Day High Low • Dec 16New 90-day high: kr29.30The company is up 14% from its price of kr25.75 on 17 September 2020. The Swedish market is up 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Machinery industry, which is up 10.0% over the same period.
Is New 90 Day High Low • Nov 30New 90-day high: kr29.00The company is up 36% from its price of kr21.40 on 01 September 2020. The Swedish market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Machinery industry, which is up 14% over the same period.
Reported Earnings • Nov 07Third quarter 2020 earnings released: kr0.12 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: kr8.50m (up 143% from 3Q 2019). Net loss: kr6.10m (loss narrowed 32% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has increased by 25% per year, which means it is tracking significantly ahead of earnings growth.
Is New 90 Day High Low • Oct 29New 90-day low: kr21.35The company is down 28% from its price of kr29.65 on 30 July 2020. The Swedish market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 3.0% over the same period.
お知らせ • Oct 08Cell Impact AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 175 million.Cell Impact AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 175 million. Security Name: Series B Shares Security Type: Common Stock Securities Offered: 7,000,000 Price\Range: SEK 25 Transaction Features: Subsequent Direct Listing